Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer
| Autor: | Lise, M, Nitti, Donato, Marchet, A, Sahmoud, T, Buyse, M, Duez, N, Fiorentino, M, GUIMARAES DOS SANTOS, J, Labianca, R, Rougier, P, Gignooux, M, Pedrazzoli, S. |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Mitomycin medicine.medical_treatment Adenocarcinoma Disease-Free Survival law.invention Randomized controlled trial Stomach Neoplasms law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Proportional Hazards Models Chemotherapy business.industry Cancer medicine.disease Combined Modality Therapy Surgery Europe Survival Rate Clinical trial Regimen Chemotherapy Adjuvant Fluorouracil Female business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 13:2757-2763 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PURPOSE In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. PATIENTS AND METHODS Three hundred fourteen patients who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) gastric adenocarcinoma were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS Of 314 patients, 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 patients never received chemotherapy. The median number of cycles was five. Of the patients started on adjuvant treatment, severe hematologic and nonhematologic toxicity (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III patients. No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION FAM2, in view of its high toxicity, cannot be advocated as standard adjuvant treatment for gastric cancer. Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|